Takis Biotech Company
Takis is a Biotechnology Company a main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture on 07 February to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine.
The PCR technology offers several advantages including high purity, increased production speed, and absence of antibiotics and bacterial contaminants. Further, the vaccine gene developed through this technology can be effective without being inserted into the patient’s genome.
Applied DNA Sciences’ subsidiary LineaRx and Takis Biotech formed a joint venture on 07 February to develop a linear DNA vaccine as a treatment for coronavirus. The JV will use Polymerase Chain Reaction (PCR)-based DNA manufacturing technology to develop the vaccine.
The PCR technology offers several advantages including high purity, increased production speed, and absence of antibiotics and bacterial contaminants. Further, the vaccine gene developed through this technology can be effective without being inserted into the patient’s genome.
Technology:
CAR-T, Peptides and Proteins, Viral Vectors
Industry:
CAR-T, Peptides and Proteins, Viral Vectors
Headquarters:
Italy
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership